Source: yahoo_news
Source ID: yahoo:a14167ea2753b361beff9f7f6a329217:ARWR
URL: https://finance.yahoo.com/healthcare/articles/arrowhead-pharmaceuticals-announces-aro-mapt-113000381.html?.tsrc=rss
Symbol: (ARWR)
Published: 2026-10-14 07:30:00 EDT
Time precision: minute
Title: Arrowhead Pharmaceuticals Announces ARO-MAPT Interim Phase 1/2a Clinical Data Demonstrating Deep and Durable Tau Reductions in Healthy Volunteers

PASADENA, Calif., October 14, 2026--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced interim results from an ongoing Phase 1/2a study of ARO-MAPT, the company’s investigational RNA interference (RNAi) therapeutic being developed as a potential treatment for Alzheimer’s disease and other tauopathies. These results represent the first successful clinical validation of a platform to deliver siRNA across the blood-brain barrier and achieve substantial target gene knockdown in the brain